Latest & greatest articles for anticoagulation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on anticoagulation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on anticoagulation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for anticoagulation

301. Heparin versus citrate for anticoagulation in critically ill patients treated with continuous renal replacement therapy

Heparin versus citrate for anticoagulation in critically ill patients treated with continuous renal replacement therapy Heparin versus citrate for anticoagulation in critically ill patients treated with continuous renal replacement therapy Heparin versus citrate for anticoagulation in critically ill patients treated with continuous renal replacement therapy Tillman J CRD summary The author concluded that regional citrate anticoagulation was associated with increased haemofilter circuit survival (...) time and lower risk of bleeding, compared with systemic heparin anticoagulation in continuous renal replacement therapy for patients with acute renal failure. The reliability of this conclusion is unclear, given restrictions in the search strategy, and failure to minimise errors and bias in the review process. Authors' objectives To compare systemic heparin and regional citrate anticoagulation in continuous renal replacement therapy for patients with acute renal failure. Searching The Cochrane

2009 DARE.

302. Is patient self-monitoring (including self-testing and selfmanagement) of oral anticoagulation therapy safe, efficacious and cost-effective?

Is patient self-monitoring (including self-testing and selfmanagement) of oral anticoagulation therapy safe, efficacious and cost-effective? Is patient self-monitoring (including self-testing and selfmanagement) of oral anticoagulation therapy safe, efficacious and cost-effective? Is patient self-monitoring (including self-testing and selfmanagement) of oral anticoagulation therapy safe, efficacious and cost-effective? Myles S Record Status This is a bibliographic record of a published health (...) technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Myles S. Is patient self-monitoring (including self-testing and selfmanagement) of oral anticoagulation therapy safe, efficacious and cost-effective? Glasgow: Quality Improvement Scotland (NHS QIS ). Evidence Note 27. 2009 Authors' conclusions Recent systematic reviews and meta analyses indicate that for selected and well trained patients, self-monitoring

2009 Health Technology Assessment (HTA) Database.

303. Use of point-of-care devices in patients with oral anticoagulation : a health technology assessment

Use of point-of-care devices in patients with oral anticoagulation : a health technology assessment Use of point-of-care devices in patients with oral anticoagulation : a Health Technology Assessment Use of point-of-care devices in patients with oral anticoagulation : a Health Technology Assessment Gailly J, Gerkens S, Van Den Bruel A, Devriese S, Obyn C,Cleemput I Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation (...) of the quality of this assessment has been made for the HTA database. Citation Gailly J, Gerkens S, Van Den Bruel A, Devriese S, Obyn C,Cleemput I. Use of point-of-care devices in patients with oral anticoagulation : a Health Technology Assessment. Brussels: Belgian Health Care Knowledge Centre (KCE). KCE Reports 117C. 2009 Authors' conclusions Compared with laboratory INR testing, the testing of INR with point-of-care devices is a good option for patients with long term anticoagulation with vitamine K

2009 Health Technology Assessment (HTA) Database.

304. Dabigatran or Rivaroxaban versus other anticoagulants for thromboprophylaxis after major orthopedic surgery: systematic review of comparative clinical-effectiveness and safety

Dabigatran or Rivaroxaban versus other anticoagulants for thromboprophylaxis after major orthopedic surgery: systematic review of comparative clinical-effectiveness and safety Dabigatran or Rivaroxaban versus other anticoagulants for thromboprophylaxis after major orthopedic surgery: systematic review of comparative clinical-effectiveness and safety Dabigatran or Rivaroxaban versus other anticoagulants for thromboprophylaxis after major orthopedic surgery: systematic review of comparative (...) clinical-effectiveness and safety Ndegwa S, Moulton K, Argaez C Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Ndegwa S, Moulton K, Argaez C. Dabigatran or Rivaroxaban versus other anticoagulants for thromboprophylaxis after major orthopedic surgery: systematic review of comparative clinical-effectiveness and safety . Ottawa: Canadian Agency

2009 Health Technology Assessment (HTA) Database.

305. Cost-effectiveness analysis of anticoagulation strategies in non-ST-elevation acute coronary syndromes

Cost-effectiveness analysis of anticoagulation strategies in non-ST-elevation acute coronary syndromes Cost-effectiveness analysis of anticoagulation strategies in non-ST-elevation acute coronary syndromes Cost-effectiveness analysis of anticoagulation strategies in non-ST-elevation acute coronary syndromes Maxwell CB, Holdford DA, Crouch MA, Patel DA Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains (...) a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to compare the cost-effectiveness of four anticoagulation regimens that were recommended for moderate-to-high-risk patients with non-ST-elevation acute coronary syndrome. Bivalirudin was the least costly anticoagulation therapy for early invasive treatment, and fondaparinux was preferred for patients undergoing

2009 NHS Economic Evaluation Database.

306. The cost-effectiveness of computer-assisted anticoagulant dosage: results from the European Action on Anticoagulation (EAA) multicentre study

The cost-effectiveness of computer-assisted anticoagulant dosage: results from the European Action on Anticoagulation (EAA) multicentre study Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 NHS Economic Evaluation Database.

307. 6 or 3 months of anticoagulant therapy did not differ for treatment failure in patients with DVT, PE, or both

6 or 3 months of anticoagulant therapy did not differ for treatment failure in patients with DVT, PE, or both 6 or 3 months of anticoagulant therapy did not differ for treatment failure in patients with DVT, PE, or both | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here 6 or 3 months of anticoagulant therapy did not differ for treatment failure in patients with DVT, PE, or both Article Text Therapeutics 6 or 3 months of anticoagulant

2008 Evidence-Based Medicine

308. Review: oral anticoagulants plus aspirin reduce arterial thromboembolism more than oral anticoagulants alone but only in patients with mechanical heart valves

Review: oral anticoagulants plus aspirin reduce arterial thromboembolism more than oral anticoagulants alone but only in patients with mechanical heart valves Review: oral anticoagulants plus aspirin reduce arterial thromboembolism more than oral anticoagulants alone but only in patients with mechanical heart valves | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time (...) . To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: oral anticoagulants plus aspirin reduce arterial thromboembolism more

2008 Evidence-Based Nursing

309. Anticoagulation - warfarin.

Anticoagulation - warfarin. Guidelines and Measures | Agency for Healthcare Research & Quality HHS.gov Search ahrq.gov Search ahrq.gov Menu Topics A - Z Healthcare Delivery Latest available findings on quality of and access to health care Searchable database of AHRQ Grants, Working Papers & HHS Recovery Act Projects AHRQ Projects funded by the Patient-Centered Outcomes Research Trust Fund You are here Guidelines and Measures Funding for the National Guideline Clearinghouse (NGC) has ended

2008 Singapore Ministry of Health

310. An abnormal D-dimer test result indicated that anticoagulant therapy should be continued

An abnormal D-dimer test result indicated that anticoagulant therapy should be continued An abnormal D-dimer test result indicated that anticoagulant therapy should be continued | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here An abnormal D-dimer test result indicated that anticoagulant therapy should be continued Article Text Therapeutics An abnormal D-dimer test result indicated that anticoagulant therapy should be continued Statistics

2008 Evidence-Based Medicine

311. Suturing extraction sockets on patients maintained on oral anticoagulants. Full Text available with Trip Pro

Suturing extraction sockets on patients maintained on oral anticoagulants. A randomised controlled trial (RCT) was carried out.Patients scheduled for dental extraction were randomly divided into four groups: no suturing with either discontinued anticoagulants (group 1) or continued warfarin (group 2); and suturing with either discontinued anticoagulants (group 3) or continued warfarin (group 4). The international normalised ratio (INR) was determined at different timepoints (baseline, days 1, 3 (...) but insignificant incidence of bleeding postoperatively compared with their respective controls.Dental extractions may be safely performed for people who are taking anticoagulation therapy provided the INR level is kept >/=3.0 and effective measures of local haemostasis are administered. The decision to suture should be made on a case-by-case basis, as the trauma associated with soft tissue handling might outweigh its advantages in some situations, such as simple extractions.

2008 Evidence-based dentistry Controlled trial quality: uncertain

312. Genetic determinants of response to warfarin during initial anticoagulation. Full Text available with Trip Pro

Genetic determinants of response to warfarin during initial anticoagulation. Genetic variants of the enzyme that metabolizes warfarin, cytochrome P-450 2C9 (CYP2C9), and of a key pharmacologic target of warfarin, vitamin K epoxide reductase (VKORC1), contribute to differences in patients' responses to various warfarin doses, but the role of these variants during initial anticoagulation is not clear.In 297 patients starting warfarin therapy, we assessed CYP2C9 genotypes (CYP2C9 *1, *2, and *3

2008 NEJM

313. Feasibility, cost-effectiveness and patients' acceptance of point-of-care INR testing in a hospital-based anticoagulation clinic

Feasibility, cost-effectiveness and patients' acceptance of point-of-care INR testing in a hospital-based anticoagulation clinic Feasibility, cost-effectiveness and patients' acceptance of point-of-care INR testing in a hospital-based anticoagulation clinic Feasibility, cost-effectiveness and patients' acceptance of point-of-care INR testing in a hospital-based anticoagulation clinic Kong MC, Lim TG, Ng HJ, Chan YH, Lee LH Record Status This is a critical abstract of an economic evaluation (...) be implemented, in busy hospital anticoagulation clinics, with mechanisms to address increased variation in INR at higher ranges. The methods and reporting aligned well with creating a monitoring protocol. For a formal economic evaluation, additional costs and outcomes should be considered. Type of economic evaluation Cost-effectiveness analysis Study objective This study evaluated the intervention costs, patient satisfaction, and time saved with the CoaguChek portable point-of-care coagulometer

2008 NHS Economic Evaluation Database.

314. Review: low-molecular-weight heparin prevented recurrent VTE more than oral anticoagulants in patients with cancer

Review: low-molecular-weight heparin prevented recurrent VTE more than oral anticoagulants in patients with cancer Review: low-molecular-weight heparin prevented recurrent VTE more than oral anticoagulants in patients with cancerCommentary | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: low-molecular-weight heparin prevented recurrent VTE more than oral anticoagulants in patients with cancerCommentary Article Text Treatment Review

2008 Evidence-Based Nursing

315. Risk of fatal pulmonary embolism was 0.49 per 100 person-years after discontinuing anticoagulant therapy for venous thromboembolism

Risk of fatal pulmonary embolism was 0.49 per 100 person-years after discontinuing anticoagulant therapy for venous thromboembolism Risk of fatal pulmonary embolism was 0.49 per 100 person-years after discontinuing anticoagulant therapy for venous thromboembolism | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see (...) our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Risk of fatal pulmonary embolism was 0.49 per 100 person-years after discontinuing anticoagulant therapy for venous

2008 Evidence-Based Medicine

316. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review

Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 DARE.

317. Clinical evidence for rebound hypercoagulability after discontinuing oral anticoagulants for venous thromboembolism

Clinical evidence for rebound hypercoagulability after discontinuing oral anticoagulants for venous thromboembolism Clinical evidence for rebound hypercoagulability after discontinuing oral anticoagulants for venous thromboembolism Clinical evidence for rebound hypercoagulability after discontinuing oral anticoagulants for venous thromboembolism Cundiff DK CRD summary This review concluded that increasing the duration of oral anticoagulation treatment for venous thromboembolism did (...) not significantly reduce overall adverse events. Rebound hypercoagulability accounted for approximately 2% of patients who experienced recurrent venous thromboembolism in the two months following treatment discontinuation. Significant flaws in the review mean that the reliability of this conclusion is unclear. Authors' objectives To assess the extent to which rebound hypercoagulability-related venous thromboembolism recurrences occur in the two months following discontinuation of oral anticoagulants. Searching

2008 DARE.

318. Oral anticoagulants and non-cardioembolic stroke prevention

Oral anticoagulants and non-cardioembolic stroke prevention Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 DARE.

319. Effect of setting, monitoring intensity and patient experience on anticoagulation control: a systematic review and meta-analysis of the literature

Effect of setting, monitoring intensity and patient experience on anticoagulation control: a systematic review and meta-analysis of the literature Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 DARE.

320. Anticoagulant prophylaxis to prevent asymptomatic deep vein thrombosis in hospitalized medical patients: a systematic review and meta-analysis

Anticoagulant prophylaxis to prevent asymptomatic deep vein thrombosis in hospitalized medical patients: a systematic review and meta-analysis Anticoagulant prophylaxis to prevent asymptomatic deep vein thrombosis in hospitalized medical patients: a systematic review and meta-analysis Anticoagulant prophylaxis to prevent asymptomatic deep vein thrombosis in hospitalized medical patients: a systematic review and meta-analysis Lloyd N S, Douketis J D, Moinuddin I, Lim W, Crowther M A CRD summary (...) This review concluded that anticoagulant prophylaxis in hospitalised at-risk medical patients reduced the risk of asymptomatic deep vein thrombosis, but increased the risk of major bleeding, in comparison with placebo. Although the authors’ conclusions were based on only a small number of studies, this was a well-conducted review and its findings were supported by the data presented. Authors' objectives To compare the risk of asymptomatic deep vein thrombosis (DVT) in at-risk hospital medical patients

2008 DARE.